Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, ≥ 70 years of age.~* Cancer of the colon or rectum.~* Metastatic disease diagnosed ≤ 6 months before enrollment.~* ≥ 1 measurable metastatic lesion.~Exclusion Criteria:~* Adjuvant anti-vascular endothelial growth factor (VEGF) treatment.~* Prior chemotherapeutic treatment for metastatic colorectal cancer.~* Past or current history of other malignancies (with the exception of basal and squamous cell cancer of the skin, or in situ cancer of the cervix).~* Clinically significant cardiovascular disease.~* Current or recent daily use of aspirin (\> 325 mg/day) or other non-steroidal anti-inflammatory drug (NSAID), or full dose anticoagulants.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab + capecitabine (Type: EXPERIMENTAL): Participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3-week treatment cycle. In addition, participants received capecitabine 1000 mg/m\^2 orally twice daily on Days 1-14 of each 3-week treatment cycle.
- Capecitabine (Type: ACTIVE_COMPARATOR): Participants received capecitabine 1000 mg/m\^2 orally twice daily on Days 1-14 of each 3-week treatment cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).